You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
华润医药(03320.HK)生物药获纳入国家医保目录 料年销售逾2亿人币
阿思达克 11-28 14:55

华润医药(03320.HK)公布,旗下生物药瑞通立(瑞替普(酉每))获国家医疗保障局纳入2019年新版国家医保目录,预期受惠於进入国家基药目录和医保目录的双重政策,产品年销售规模有望超过2亿元人民币(下同)。

瑞通立主要用於治疗急性心肌梗塞,目前已获批急性脑卒中和急性肺栓塞的新适应症,正处於临床Ⅱ期研究阶段,下肢深静脉血栓的新适应症临床研究申请於年内提交。华润医药指,未来如新适应症可获批,瑞通立的市场规模将进一步扩大至5亿元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account